Suchergebnisse - Portal für Medizinische Datenmodelle (MDM-Portal)

Screening Biopsy GOAL Trial B-cell Lymphoma NCT02499003

- 20.09.21 - 1 Formular, 3 Itemgruppen, 22 Datenelemente, 1 Sprache

Itemgruppen: Admininstrative data, Bone marrow biopsy, Biopsy Tumor

NCT02499003 The GOAL Trial: Rescue Treatment With the Monoclonal Anti CD20-antibody Obinutuzumab (GA101) in Combination With Pixantrone for the Treatment of Patients With Relapsed Aggressive B-cell Lymphoma Source: Prof. Dr. med. Georg Heß Universitätsmedizin Mainz

Iodine-131 Anti-B1 Antibody for Non Hodgkin’s Lymphomas NCT00996593 - Central Pathology Assessment and Description

- 20.09.21 - 1 Formular, 7 Itemgruppen, 21 Datenelemente, 1 Sprache

Itemgruppen: Biopsy, Biopsy , Lymphoma, Non-Hodgkin | Classification, Pathologist evaluation | Central, Basis of Assessment, Pathologist evaluation | Central | Description, Administrative

Study ID: 104507 Clinical Study ID: BEX104507 Study Title: Phase II Study of Iodine-131 Anti-B1 Antibody for Non Hodgkin’s Lymphoma Patients who have Previously Received Rituximab Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00996593 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin

Local Pathology Results GSK study Prostatic neoplasms NCT00883909

- 20.09.21 - 1 Formular, 2 Itemgruppen, 12 Datenelemente, 1 Sprache

Itemgruppen: Administrative data, Pathology Results

Study ID: 103094 Clinical Study ID: ARI103094 Study Title: ARI103094-Follow-Up Study for REDUCE Study Subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00883909 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: dutasteride Trade Name: Zytefor,Zyfetor,Duagen,Avolve,Avodart,Avidart Study Indication: Neoplasms, Prostate CRF Seiten: 934-977

Leukemia Daunorubicin Cytarabine Oblimersen NCT00085124 CALGB - Cytogenetics

- 20.09.21 - 1 Formular, 1 Itemgruppe, 25 Datenelemente, 1 Sprache

Itemgruppe: Cytogenetics

CALGB: CYTOGENETICS REFERRAL FORM NCT00085124 Daunorubicin and Cytarabine With or Without Oblimersen in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=B229EF62-6ADF-5120-E034-0003BA12F5E7

CALGB_40302_TISS_TRCK_FRM NCT00390455

- 20.09.21 - 1 Formular, 3 Itemgruppen, 24 Datenelemente, 1 Sprache

Itemgruppen: Header, Patient demographics, TISSUE TRACKING

CALGB: 40302 TISSUE TRACKING FORM NCT00390455 Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=F5AC8F60-F3F9-0DB4-E034-0003BA3F9857

CALGB: 90104 SPECIMEN SUBMISSION FORM NCT00014534

- 20.09.21 - 1 Formular, 3 Itemgruppen, 23 Datenelemente, 1 Sprache

Itemgruppen: Header, Patient demographics, SPECIMEN SUBMISSION

CALGB: 90104 SPECIMEN SUBMISSION FORM NCT00014534 Combination Chemotherapy in Treating Patients With Bladder Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=E5F4A97F-274E-398C-E034-0003BA3F9857

Pathology - Leukemia Pathology Form - Cytogenetics - 2019350v3.0 - Leukemia Pathology Form - Cytogenetics

- 20.09.21 - 1 Formular, 3 Itemgruppen, 47 Datenelemente, 1 Sprache

Itemgruppen: CRF Header, Pathology: Form Administration, Pathology: Cytogenetic Assessment

Leukemia Pathology Form - Cytogenetics Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=1B4D83AE-8665-6A50-E044-0003BA3F9857

Brain and Central Nervous System Tumors NCT00887146 Pathology - North Central Cancer Treatment Group N0577 Pathology Submission Form - 2745984v1.0 - North Central Cancer Treatment Group N0577 Pathology Submission Form

- 20.09.21 - 1 Formular, 4 Itemgruppen, 20 Datenelemente, 1 Sprache

Itemgruppen: Header, Header, Institution Contact Information (Please Print), Footer Module

North Central Cancer Treatment Group N0577 Pathology Submission Form Radiation Therapy or Radiation Therapy and Temozolomide or Temozolomide Alone in Treating Patients With Newly Diagnosed Anaplastic Glioma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=4C08FC47-BFC6-632C-E044-0003BA3F9857

Pathology - Lung Cancer - North Central Cancer Treatment Group N0723 Pathology Reporting Form - 2731651v1.0 - Lung Cancer - North Central Cancer Treatment Group N0723 Pathology Reporting Form

- 20.09.21 - 1 Formular, 9 Itemgruppen, 59 Datenelemente, 1 Sprache

Itemgruppen: Header Module, Pathology Reporting, Lung Surgery, Disease Characteristics, Disease Characteristics2, Comments and Pathology Reporting, EGFR FISH Status, EGFR IHC Status, Comments and Pathology Reporting2

North Central Cancer Treatment Group N0723 Pathology Reporting Form; ***This CRF DELETED FROM STUDY, so no response to initial CDE-compliance review.*** Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=46FF63E8-1059-1831-E044-0003BA3F9857

Pathology Reporting Form - Brain Tumor N0577

- 20.09.21 - 1 Formular, 4 Itemgruppen, 34 Datenelemente, 1 Sprache

Itemgruppen: Header, I. CRA/RN, II. Completed by the NCCTG Pathology reviewer, Comments and Pathology Reporting

North Central Cancer Treatment Group N0577 Pathology Reporting Form - Brain Tumor Radiation Therapy or Radiation Therapy and Temozolomide or Temozolomide Alone in Treating Patients With Newly Diagnosed Anaplastic Glioma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=4CA85A1E-6D87-49C3-E044-0003BA3F9857

North Central Cancer Treatment Group Arms A & D Only Recurrent Research Tissue Submission Form NCT00079274

- 20.09.21 - 1 Formular, 3 Itemgruppen, 29 Datenelemente, 1 Sprache

Itemgruppen: Header module, Visit, Instructions

North Central Cancer Treatment Group Arms A and D Only Recurrent Research Tissue Submission Form NCT00079274 Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=8BC1F4CF-E66A-E266-E040-BB89AD436B4E

AML Material Submission Form Pathology NCT00049517 - Material Submission Form Pathology AML E1900 NCT00049517

- 20.09.21 - 1 Formular, 3 Itemgruppen, 31 Datenelemente, 1 Sprache

Itemgruppen: Header, Completed by submitting institutions, Completed by central lab

E1900 Material Submission Form Combination Chemotherapy With or Without Monoclonal Antibody Therapy Followed by Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia NCT00049517 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=A727E0B4-B257-2F80-E034-0003BA0B1A09

Stichworte

Inhaltsverzeichnis

Ausgewählte Datenmodelle